FMP
Virtus LifeSci Biotech Clinical Trials ETF
BBC
AMEX
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
27.58 USD
0.0483 (0.175%)
Valuation Date:
Oct 2, 2024 1:55 PM
Share Price on Valuation Date
$27.58
Stock Beta
0.96
Shares Outstanding
405720